Mitchell Kapoor Reaffirms Buy Rating for Summit Therapeutics Amid Promising Ivonescimab Trial Results
Truist Financial Maintains Summit Therapeutics(SMMT.US) With Buy Rating
Jefferies Maintains Summit Therapeutics(SMMT.US) With Buy Rating, Maintains Target Price $31
Cantor Fitzgerald Maintains Summit Therapeutics(SMMT.US) With Buy Rating
Why Summit Therapeutics Inc. (SMMT) Went Up On Wednesday
Health Care Ticks Up Ahead of Earnings -- Health Care Roundup
Why Is Summit Therapeutics Stock Soaring On Wednesday?
Express News | Cantor Fitzgerald Reiterates Overweight on Summit Therapeuticsto Overweight
Summit Therapeutics Analyst Ratings
Amphenol Posts Better-Than-Expected Results, Joins SAP, Tesla, Pegasystems And Other Big Stocks Moving Higher On Wednesday
Trending Stocks Today | Ensysce Biosciences Shoots up 85.56%
Sector Update: Health Care Stocks Flat to Higher Premarket Wednesday
Express News | Summit Therapeutics Shares Are Trading Higher After the Company Provided Updates on Its Phase 3 Trial of Ivonescimab and Announced It Met Its Primary Endpoint
Truist Financial Reaffirms Their Buy Rating on Summit Therapeutics (SMMT)
S&P 500 Futures Rise In Premarket Trading; Pegasystems, Popular Inc. Lead
Summit Therapeutics Rallies After Lung Cancer Drug Shows Positive Results
Express News | Summit Therapeutics Shares up 11.4% Premarket After Co, Partner Akeso's Lung Cancer Treatment Meets Main Goal in Late Stage Trial Conducted in China
Summit Therapeutics' Partner Akeso HARMONi-6/AK112-306 Phase 3 Trial Of Ivonescimab In Combination With Platinum-based Chemotherapy Compared With Tislelizumab Met Its Primary Endpoint Of Progression-Free Survival For Locally Advanced Or Metastatic...
Express News | Summit Therapeutics Inc - No New Safety Signals Identified in Phase III Study
Express News | Summit Therapeutics Inc - Harmoni-6 Phase III Trial Meets Primary Endpoint of Pfs